Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Por:
Du, Y, Carrio, I, De Vincentis, G, Fanti, S, Ilhan, H, Mommsen, C, Nitzsche, E, Sundram, F, Vogel, W, Oyen, W, Lewington, V
Publicada:
1 sep 2017
Resumen:
Purpose Radium Ra 223 dichloride (radium-223, Xofigo (R)) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. We provide straightforward and practical recommendations for European nuclear medicine centres to optimize radium-223 service provision.
Methods An independent research consultancy agency observed radium-223 procedures and conducted interviews with all key staff members involved in radium-223 treatment delivery in 11 nuclear medicine centres across six countries (Germany, Italy, the Netherlands, Spain, Switzerland and the UK) experienced in administering radium-223. The findings were collated and discussed at a meeting of experts from these centres, during which key consensus recommendations were defined.
Results The recommendations cover centre organization and preparation; patient referral; radium-223 ordering, preparation and disposal; radium-223 treatment delivery/administration; and patient experience. Guidance includes structured coordination and communication within centres and multidisciplinary teams, focusing on sharing best practice to provide high-quality, patient-centred care throughout the treatment pathway.
Conclusions These expert recommendations are intended to complement existing management guidelines. Sharing best practice and experience will help nuclear medicine centres to optimize radium-223 service provision and improve patient care.
Filiaciones:
Du, Y:
Royal Marsden NHS Fdn Trust, Dept Nucl Med & PET CT, Fulham Rd, London SW3 6JJ, England
Carrio, I:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
De Vincentis, G:
Policlin Umberto I Univ Hosp Rome, Rome, Italy
Fanti, S:
Univ Hosp Bologna, Bologna, Italy
Ilhan, H:
Ludwig Maximilians Univ Hosp, Munich, Germany
Mommsen, C:
Nuklearmed Berlin, Berlin, Germany
Nitzsche, E:
Canton Hosp Aarau, Aarau, Switzerland
Sundram, F:
Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
Vogel, W:
Netherlands Canc Inst, Amsterdam, Netherlands
Oyen, W:
Royal Marsden NHS Fdn Trust, Dept Nucl Med & PET CT, Fulham Rd, London SW3 6JJ, England
Inst Canc Res, London, England
Lewington, V:
Guys & St Thomas NHS Fdn Trust, London, England
Green Published
|